Novaliq receives FDA nod for Vevye
Novaliq has obtained the Food and Drug Administration’s permission for Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.
Vevye is the only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks, Novaliq said.
“We are proud that FDA approved Vevyve. The safety and efficacy of Vevye were assessed in a total of 1,369 patients with dry eye disease, of which 738 received Vevye. Vevye and its novel vehicle were safe, well tolerated and demonstrated early, consistent and durable therapeutic effects,” said Sonja Krösser, vice president of medical science and regulatory affairs at Novaliq. “It is an exciting moment when you have followed science that finally led into a new category of water-free ocular therapies addressing unmet medical needs for patients suffering from dry eye disease.”
Dry eye disease affects millions of Americans and is one of the most common ocular surface disorders. A leading cause of DED is inflammation of the ocular surface. The chronic inflammatory nature causes progressive corneal surface damage that can lead to direct or indirect visual impairment.
[Read more: Minding the most critical of the senses]
Vevye is cyclosporine, solubilized in a novel, water-free excipient and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy. The solution does not contain water or anti-microbial preservatives, oils or surfactants. As a water-free product, there is no associated pH and no osmolarity.
"Vevye addresses the well documented underlying inflammatory root cause of dry eye disease, repeatedly demonstrating early and clinically meaningful efficacy upon both signs and symptoms,” said John Sheppard, professor of ophthalmology at Eastern Virginia Medical School, and Mid-Atlantic Medical director for Eye Care Partners and investigator in the development program. “The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis. Vevye is an exceptionally well tolerated formulation, combining a novel, first-in-class vehicular delivery system with by far the most established and safe topical active pharmaceutical ingredient, cyclosporine, providing a major advancement for our patients.”
“I am thrilled that a novel water-free, non-preserved pharmaceutical option for the treatment of the signs and symptoms of dry eye was approved by the FDA,” said Jade Coats, optometric physician at McDonald Eye Associates in Rogers, Ark. and member of the Intrepid Eye Society. “With the most potent commercially available cyclosporine 0.1%, Vevye brings to the table excellent comfort and tolerability, fast onset of symptom relief, and a strategically effective drop size, providing patients and practitioners an additional anti-inflammatory, immunomodulating option for the treatment of dry eye disease.”
[Read more: Eye and ear care still driven by pandemic-related trends]
“The U.S. FDA approval of Vevye marks a milestone for patients and care takers by addressing a significant unmet need for millions of people suffering with this disease,” said Christian Roesky, CEO of Novaliq. “With now two EyeSol based and water-free dry eye drug therapies approved by FDA, Novaliq has established a novel category of non-aqueous, non-preserved ophthalmic drugs with the opportunity to become a standard of care in ophthalmology in the future. We will continue to execute on our mission to transform ocular therapies by developing breakthrough novel EyeSol therapies way beyond dry eye disease.”